Spire Healthcare Group (LON:SPI) Stock Price Down 16.3% After Analyst Downgrade

Spire Healthcare Group plc (LON:SPI) shares were down 16.3% during mid-day trading on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 188 ($2.43). Approximately 4,929,258 shares changed hands during trading, an increase of 648% from the average daily volume of 658,925 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Stock Down 6.0 %

The company has a current ratio of 0.70, a quick ratio of 0.74 and a debt-to-equity ratio of 62.25. The firm has a market cap of £711.58 million, a P/E ratio of 25.22, a PEG ratio of 1.06 and a beta of 0.96. The company’s 50 day simple moving average is GBX 227.28 and its 200-day simple moving average is GBX 229.74.

Spire Healthcare Group (LON:SPI) last released its quarterly earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) EPS for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. Research analysts forecast that Spire Healthcare Group plc will post 15.6634747 earnings per share for the current fiscal year.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.